當(dāng)前位置：首頁(yè) SCI期刊 SCIE期刊醫(yī)學(xué) 中科院4區(qū) JCRQ3 期刊介紹(非官網(wǎng))

Oncotargets And TherapySCIE

國(guó)際簡(jiǎn)稱：ONCOTARGETS THER 參考譯名：腫瘤靶點(diǎn)和治療

中科院分區(qū)
4區(qū)
CiteScore分區(qū)
Q1
JCR分區(qū)
Q3

基本信息：: ISSN：1178-6930; E-ISSN：1178-6930; 是否OA：開放; 是否預(yù)警：是; TOP期刊：否

出版信息：: 出版地區(qū)：ENGLAND; 出版商：Dove Medical Press Ltd.; 出版語(yǔ)言：English; 出版周期：1 issue/year; 出版年份：2008; 研究方向：BIOTECHNOLOGY & APPLIED MICROBIOLOGY-ONCOLOGY

評(píng)價(jià)信息：: 影響因子：2.7; H-index：44; CiteScore指數(shù)：9.7; SJR指數(shù)：0.81; SNIP指數(shù)：0.648

發(fā)文數(shù)據(jù)：: Gold OA文章占比：96.46%; 研究類文章占比：56.00%; 年發(fā)文量：75; 自引率：0; 開源占比：0.9788; 出版撤稿占比：0.0179...; 出版國(guó)人文章占比：0.86; OA被引用占比：1

投稿咨詢加急見刊

英文簡(jiǎn)介期刊介紹 CiteScore數(shù)據(jù) 中科院SCI分區(qū) JCR分區(qū) 發(fā)文數(shù)據(jù) 常見問題

英文簡(jiǎn)介Oncotargets And Therapy期刊介紹

OncoTargets and Therapy is an international, peer-reviewed journal focusing on molecular aspects of cancer research, that is, the molecular diagnosis of and targeted molecular or precision therapy for all types of cancer.

The journal is characterized by the rapid reporting of high-quality original research, basic science, reviews and evaluations, expert opinion and commentary that shed novel insight on a cancer or cancer subtype.

Specific topics covered by the journal include:

-Novel therapeutic targets and innovative agents

-Novel therapeutic regimens for improved benefit and/or decreased side effects

-Early stage clinical trials

Further considerations when submitting to OncoTargets and Therapy:

-Studies containing in vivo animal model data will be considered favorably.

-Tissue microarray analyses will not be considered except in cases where they are supported by comprehensive biological studies involving multiple cell lines.

-Biomarker association studies will be considered only when validated by comprehensive in vitro data and analysis of human tissue samples.

-Studies utilizing publicly available data (e.g. GWAS/TCGA/GEO etc.) should add to the body of knowledge about a specific disease or relevant phenotype and must be validated using the authors’ own data through replication in an independent sample set and functional follow-up.

-Bioinformatics studies must be validated using the authors’ own data through replication in an independent sample set and functional follow-up.

-Single nucleotide polymorphism (SNP) studies will not be considered.

期刊簡(jiǎn)介Oncotargets And Therapy期刊介紹

《Oncotargets And Therapy》自2008出版以來(lái)，是一本醫(yī)學(xué)優(yōu)秀雜志。致力于發(fā)表原創(chuàng)科學(xué)研究結(jié)果，并為醫(yī)學(xué)各個(gè)領(lǐng)域的原創(chuàng)研究提供一個(gè)展示平臺(tái)，以促進(jìn)醫(yī)學(xué)領(lǐng)域的的進(jìn)步。該刊鼓勵(lì)先進(jìn)的、清晰的闡述，從廣泛的視角提供當(dāng)前感興趣的研究主題的新見解，或?qū)彶槎嗄陙?lái)某個(gè)重要領(lǐng)域的所有重要發(fā)展。該期刊特色在于及時(shí)報(bào)道醫(yī)學(xué)領(lǐng)域的最新進(jìn)展和新發(fā)現(xiàn)新突破等。該刊近一年被列入預(yù)警期刊名單，目前已被權(quán)威數(shù)據(jù)庫(kù)SCIE收錄，得到了廣泛的認(rèn)可。

該期刊投稿重要關(guān)注點(diǎn)：

預(yù)計(jì)審稿時(shí)間：較慢,6-12周
醫(yī)學(xué)
BIOTECHNOLOGY & APPLIED MICROBIOLOGY
SCIE
中科院4區(qū)
預(yù)警

Cite Score數(shù)據(jù)（2024年最新版）Oncotargets And Therapy Cite Score數(shù)據(jù)

CiteScore：9.7
SJR：0.81
SNIP：0.648

學(xué)科類別	分區(qū)	排名	百分位
大類：Medicine 小類：Pharmacology (medical)	Q1	23 / 272	91%
大類：Medicine 小類：Oncology	Q1	65 / 404	84%

CiteScore 是由Elsevier(愛思唯爾)推出的另一種評(píng)價(jià)期刊影響力的文獻(xiàn)計(jì)量指標(biāo)。反映出一家期刊近期發(fā)表論文的年篇均引用次數(shù)。CiteScore以Scopus數(shù)據(jù)庫(kù)中收集的引文為基礎(chǔ)，針對(duì)的是前四年發(fā)表的論文的引文。CiteScore的意義在于，它可以為學(xué)術(shù)界提供一種新的、更全面、更客觀地評(píng)價(jià)期刊影響力的方法，而不僅僅是通過影響因子(IF)這一單一指標(biāo)來(lái)評(píng)價(jià)。

歷年Cite Score趨勢(shì)圖

中科院SCI分區(qū)Oncotargets And Therapy 中科院分區(qū)

中科院 2023年12月升級(jí)版 綜述期刊：否 Top期刊：否

大類學(xué)科	分區(qū)	小類學(xué)科	分區(qū)
醫(yī)學(xué)	4區(qū)	BIOTECHNOLOGY & APPLIED MICROBIOLOGY 生物工程與應(yīng)用微生物 ONCOLOGY 腫瘤學(xué)	3區(qū) 4區(qū)

中科院分區(qū)表 是以客觀數(shù)據(jù)為基礎(chǔ)，運(yùn)用科學(xué)計(jì)量學(xué)方法對(duì)國(guó)際、國(guó)內(nèi)學(xué)術(shù)期刊依據(jù)影響力進(jìn)行等級(jí)劃分的期刊評(píng)價(jià)標(biāo)準(zhǔn)。它為我國(guó)科研、教育機(jī)構(gòu)的管理人員、科研工作者提供了一份評(píng)價(jià)國(guó)際學(xué)術(shù)期刊影響力的參考數(shù)據(jù)，得到了全國(guó)各地高校、科研機(jī)構(gòu)的廣泛認(rèn)可。

中科院分區(qū)表 將所有期刊按照一定指標(biāo)劃分為1區(qū)、2區(qū)、3區(qū)、4區(qū)四個(gè)層次，類似于“優(yōu)、良、及格”等。最開始，這個(gè)分區(qū)只是為了方便圖書管理及圖書情報(bào)領(lǐng)域的研究和期刊評(píng)估。之后中科院分區(qū)逐步發(fā)展成為了一種評(píng)價(jià)學(xué)術(shù)期刊質(zhì)量的重要工具。

歷年中科院分區(qū)趨勢(shì)圖

JCR分區(qū)Oncotargets And Therapy JCR分區(qū)

2023-2024 年最新版

按JIF指標(biāo)學(xué)科分區(qū)	收錄子集	分區(qū)	排名	百分位
學(xué)科：BIOTECHNOLOGY & APPLIED MICROBIOLOGY	SCIE	Q3	90 / 174	48.6%
學(xué)科：ONCOLOGY	SCIE	Q3	163 / 322	49.5%

按JCI指標(biāo)學(xué)科分區(qū)	收錄子集	分區(qū)	排名	百分位
學(xué)科：BIOTECHNOLOGY & APPLIED MICROBIOLOGY	SCIE	Q2	73 / 174	58.33%
學(xué)科：ONCOLOGY	SCIE	Q2	135 / 322	58.23%

JCR分區(qū)的優(yōu)勢(shì)在于它可以幫助讀者對(duì)學(xué)術(shù)文獻(xiàn)質(zhì)量進(jìn)行評(píng)估。不同學(xué)科的文章引用量可能存在較大的差異，此時(shí)單獨(dú)依靠影響因子(IF)評(píng)價(jià)期刊的質(zhì)量可能是存在一定問題的。因此，JCR將期刊按照學(xué)科門類和影響因子分為不同的分區(qū)，這樣讀者可以根據(jù)自己的研究領(lǐng)域和需求選擇合適的期刊。

歷年影響因子趨勢(shì)圖

發(fā)文數(shù)據(jù)

2023-2024 年國(guó)家/地區(qū)發(fā)文量統(tǒng)計(jì)

國(guó)家/地區(qū)數(shù)量
CHINA MAINLAND2784
USA135
Italy44
Japan32
Taiwan26
South Korea25
GERMANY (FED REP GER)23
Spain12
France10
Iran10

本刊中國(guó)學(xué)者近年發(fā)表論文

1、Successful Retreatment with Crizotinib After Crizotinib-Induced Liver Failure in ALK-Positive Advanced Lung Adenocarcinoma: A Case Report
Author: Zhang, Xiangming; Ni, Kai; Chen, Huijun

Journal: ONCOTARGETS AND THERAPY. 2023; Vol. 16, Issue , pp. 87-90. DOI: 10.2147/OTT.S393165
2、Role of Systemic Immunoinflammation Landscape in the Overall Survival of Patients with Leptomeningeal Metastases from Lung Cancer
Author: Wang, Jia-Wei; Yuan, Qing; Li, Li; Cao, Kai-Hua; Liu, Qi; Wang, Hong-Liang; Hu, Ke; Wu, Xi; Wan, Jing-Hai

Journal: ONCOTARGETS AND THERAPY. 2023; Vol. 16, Issue , pp. 179-187. DOI: 10.2147/OTT.S402389
3、Secondary Sinonasal Collision Tumor of Papillary Squamous Cell Carcinoma and Small Cell Neuroendocrine Carcinoma After Nasopharyngeal Carcinoma Radiotherapy: A Case Report and Literature Review of Sinonasal Collision Carcinomas
Author: Tang, Hao; Wang, Lina; Xu, Wenfeng; Xu, Yujuan; Li, Xianyun; Guo, Deyu

Journal: ONCOTARGETS AND THERAPY. 2023; Vol. 16, Issue , pp. 91-97. DOI: 10.2147/OTT.S396703
4、Ineffectiveness of Crizotinib in a Non-Small-Cell Lung Cancer with Novel ALK-LIMS1 Fusion: A Case Report
Author: Shi, Junmei; Jia, Zhaohui; Zhou, Zhiguo; Zhao, Liyan; Meng, Qingju; Liu, Yibing

Journal: ONCOTARGETS AND THERAPY. 2023; Vol. 16, Issue , pp. 109-114. DOI: 10.2147/OTT.S388962
5、Clinical Efficacy and Safety of Immunotherapy Retreatment in Metastatic Cervical Cancer: A Retrospective Study
Author: Li, Guiling; Cheng, Mingxia; Hong, Kai; Jiang, Yao

Journal: ONCOTARGETS AND THERAPY. 2023; Vol. 16, Issue , pp. 157-163. DOI: 10.2147/OTT.S400376
6、A Primary Lung and Breast Cancer Patient with Germline EGFR R776H Mutation: A Case Report and Literature Review
Author: Li, Dan; Liu, Xin; Cui, SaiQiong; Yang, DaFu; Zhu, Yue; Pan, Evenki; Yang, Peng; Dai, ZhaoXia

Journal: ONCOTARGETS AND THERAPY. 2023; Vol. 16, Issue , pp. 17-22. DOI: 10.2147/OTT.S391766
7、Transmission of Exosomal TPX2 Promotes Metastasis and Resistance of NSCLC Cells to Docetaxel
Author: Hu, Jiaru; He, Qing; Tian, Tian; Chang, Na; Qian, Liting

Journal: ONCOTARGETS AND THERAPY. 2023; Vol. 16, Issue , pp. 197-210. DOI: 10.2147/OTT.S401454
8、A Refractory Case of CDKN2A/B Loss Metastatic Intrahepatic Cholangiocarcinoma Achieving a Partial Response After First-Line Treatment with Palbociclib
Author: Fan, Weiming; Wang, Chuan; Zhong, Xuefeng; Zheng, Yating; Chen, Tingting; Huang, Mengli; Su, Shuying

Journal: ONCOTARGETS AND THERAPY. 2023; Vol. 16, Issue , pp. 23-29. DOI: 10.2147/OTT.S390458